AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06290947 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Walking Training Program
Description: The control group will engage in a standard walking training regimen, consisting of supervised treadmill sessions without the application of BFR cuffs. This protocol serves to uphold the scientific rigor of the study by offering a comparison group for the BFRw intervention.~Purpose:~To evaluate the impact of a typical exercise routine on insulin sensitivity and aerobic capacity, thereby establishing a control benchmark to contrast with the effects of the BFRw intervention.
Study NCT05845645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB0599
Description: Study participants will receive pre-specified doses of UCB0599 in 3 different formulations administered orally in a pre-specified sequence during the Treatment Periods of Part A and B
Study NCT05845645 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Study participants will receive fixed dose of esomeprazole administered orally in a pre-specified sequence during the Treatment Period of Part A. This is a non-investigational medicinal product (NIMP) in this study.
Study NCT05845645 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Study participants will receive placebo comparator administered orally in a a pre-specified sequence during the Treatment Period of Part B.
Study NCT06386237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention: Standardized breakfast with varying amounts of macronutrients (in particular carbohydrate/protein ratios)
Description: Participants receive a standardized meal with one type of macronutrient composition in one experimental session and the other type in a different experimental session a few days apart (within-subjects crossover design; i.e. order counterbalanced)
Study NCT04909541 — intervention group
Intervention type: OTHER
Intervention: CEGSSS-Canadian Endourology Group Stent Symptom Score
Description: Patient with ureteral stent complete the Canadian Endourology Group Stent Symptom Score (CEGSSS)
Study NCT04254640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine Injection
Description: Cladribine 5 mg/m2, intravenous drip,d1-5,4 weeks per cycle.
Study NCT04254640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclarubicin
Description: aclarubicin 10 mg, intravenous drip,d3-6,4 weeks per cycle.
Study NCT04254640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: G-CSF 300 µg,subcutaneous injection, d0-9,4 weeks per cycle.
Study NCT04254640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: cytarabine 10mg/ m2, subcutaneous injectionq,q12h, d3-9,4 weeks per cycle.
Study NCT05339646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSD8432 dose 1~7 and Ritonavir
Description: Cohort 1 Period 1 single dose of SSD8432 dose 1 or placebo, on day 1. Period 2: single dose of SSD8432 dose 2 or placebo , on day 7. Period 3: single dose of SSD8432 dose 3 on day 13, ritonavir or placebo, before SSD8432 dose 3 and BID on SSD8432 dosing date~Cohort 2:~Period 1 single dose of SSD8432 dose 4 or placebo, on day 1 Period 2: single doses of SSD8432 dose 5 or placebo , on day 7 Period 3: single dose of SSD8432 dose 6 on day 13, ritonavir or placebo, before SSD8432 dose 3 and BID on SSD8432 dosing date~Cohort 3:~single dose of SSD8432 dose 7 or placebo on day1. ritonavir or placebo, before SSD8432 dose 7 and BID on SSD8432 dosing date.
Study NCT05339646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSD8432 dose 8~9
Description: Cohort 4: SSD8432 dose 8 or placebo, on day 1 \~day6. Cohort 5: SSD8432 dose 9 or placebo, on day 1 \~day6.
Study NCT05339646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSD8432 dose 10~12 and ritonavir
Description: Cohort 6: SSD8432 dose 10 or placebo, on day 1 \~day6. Cohort 7: SSD8432 dose 11 or placebo, on day 1 \~day6. Cohort 8: SSD8432 dose 12 or placebo, on day 1 \~day6 Cohort 9: to be decided
Study NCT05339646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSD8432 dose 13 and Ritonavir
Description: Cohort 10:~Group A: SSD8432 dose 13, on day1 under fasting condition, on day 6 under fatty food condition, ritonavir, before SSD8432 dose 13 and BID on SSD8432 dosing date.~Group B: SSD8432 dose 13, on day1 fatty food condition, on day 6 under fasting condition ,Ritonavir, before SSD8432 dose 13 and BID on SSD8432 dosing date
Study NCT05581745 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood group A2 donor to blood group O recipient lung transplant surgery
Description: Suitable blood group A2 donor lung transplant to a consented blood group O recipient who has acceptably low levels of anti-A antibody titres and a negative virtual cross-match at time of transplant
Study NCT05339646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSD8432 dose 14 and Ritonavir
Description: Cohort 11: to be decided
Study NCT06090786 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRD assessment
Description: Bone marrow withdrawal for MRD quantification
Study NCT05475405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scapulothoracic mobilization
Description: Patient in prone lying position. The left hand of the physical therapist lifts the scapula to distract from the thoracic wall while the right hand mobilizes and stretches the inferior muscle groups attached to the scapula.
Study NCT05475405 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IASTM
Description: Restrictions and myofascial adhesions should be assessed prior to treatment along both sides using IASTM tool and a lubricant.~Once restrictions are assessed, fanning strokes at 45 degree angles to skin should be applied using the tool. This technique should be performed for 20 seconds parallel to the muscle fibers and 20 seconds perpendicular to the muscle fibers for each muscle group in scapulothoracic region. Total time for IASTM application is 10 mints. Upon completing all this patient should be given a home plan consisting of 2 different self-stretches targeting levator scapulae and upper trapezius
Study NCT04910555 — intervention group
Intervention type: OTHER
Intervention: strong desire to void - cognitive task
Description: Strong desire to void - cognitive task (verbal fluency)
Study NCT06546384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Treatment with liraglutide, following standard clinical practice as per below schedule:~Week 1: Injected dose of 0,6 mg once daily Week 2: Injected dose of 1,2 mg once daily Week 3: Injected dose of 1,8 mg once daily Week 4: Injected dose of 2,4 mg once daily From week 5 onwards: Injected dose of 3,0 mg once daily
Study NCT06546384 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight reduction recommendations (nutritional and exercise)
Description: Participants will receive nutritional and exercise recommendations and 2 telephone consultations
Study NCT06546384 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight reduction recommendations (nutritional and exercise)
Description: Participants will receive nutritional and exercise recommendations and 2 telephone consultations
Study NCT06014528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN10018
Description: 100mg QD orally (PO)
Study NCT06014528 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of IN10018
Description: 100mg QD orally (PO)
Study NCT06014528 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pegylated Liposomal Doxorubicin
Description: 40 mg/m2 once every 4 weeks (Q4W) intravenously (IV)
Study NCT06014528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin
Description: 40 mg/m2 once every 4 weeks (Q4W) intravenously (IV)
Study NCT05043064 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wet lab tasks
Description: Robotic-assisted internal thoracic artery harvesting, mitral annulus sutures placement and atrial closure in porcine model
Study NCT05416463 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Intra-Operative Device for THA
Description: The intervention group will receive primary elective THA with the use of Intellijoint HIP 3D mini-optical navigation tool.
Study NCT05416463 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-Operative Device for THA
Description: The intervention group will receive primary elective THA with the use of Intellijoint HIP 3D mini-optical navigation tool.
Study NCT05550220 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cuff Leak Test
Description: Cuff leak test is a simple and convenient tool that can be used to predict upper-airway obstruction after extubation. The CLT is used to assess airway patency through listening for an air leak and observing changes in tidal volume (VT) after the cuff is deflated.
Study NCT05550220 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cuff Leak Test
Description: Cuff leak test is a simple and convenient tool that can be used to predict upper-airway obstruction after extubation. The CLT is used to assess airway patency through listening for an air leak and observing changes in tidal volume (VT) after the cuff is deflated.
Study NCT06412042 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic BLa80
Description: Collect baby fecal samples, test for 16S rRNA, and analyze changes in the gut microbiota before and after supplementation.
Study NCT06412042 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Maltodextrin
Description: Collect baby fecal samples, test for 16S rRNA, and analyze changes in the gut microbiota before and after supplementation.
Study NCT05120934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 MG
Description: 25 mg orally for 4 weeks
Study NCT04598321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib Oral Capsule
Description: An orally available PARP inhibitor for the treatment of advanced breast cancer with germline BRCA mutations.
Study NCT05082935 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phase II Promotores de Salud
Description: Community partners (e.g., Mexican Consulate) select events for testing and use their usual outreach methods to attract participants to the site and their event. Then, at the community partner's event, the research team holds COVID-19 testing events and the Promotores de Salud health behavior intervention is delivered by bilingual research staff. The health behavior intervention includes: 1) psychoeducation to promote hand-washing, social distancing, mask wearing if unvaccinated, and continued testing to mitigate the spread of COVID-19 and psychoeducation to address vaccine hesitancy; 2) information support and service navigation to address logistical challenges associated with testing and vaccination (e.g., scheduling health care visits, transportation, language barriers); 3) motivational interviewing to explore personal, social, and behavioral barriers to testing and vaccination, and to discuss available resources.
Study NCT05082935 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phase I Promotores de Salud Outreach
Description: Testing events re-occur every two weeks at the same location and time, based on census density on Latinx individuals for site selection. Outreach conducted by promotores occurs to increase attendance at the testing events. Outreach is culturally responsive (e.g., culturally tailored radio announcements, social media posts, community canvassing, referral by community leaders).
Study NCT06554041 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental Crown with Titanium-Abutment
Description: Participants in this clinical trial will receive dental implants and single screw-retained crowns made from one of four different materials: titanium, PEEK (Polyetheretherketone), zirconia, or lithium disilicate (e.max). The implants will be placed in the posterior region of the mandible or maxillae. The study will evaluate the impact of these materials on peri-implant soft tissue health by measuring inflammatory markers in the peri-implant crevicular fluid and assessing clinical outcomes such as bleeding on probing and pocket depth at 3 and 6 months post-implantation.
Study NCT06554041 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental Crown with PEEK (Polyetheretherketone)-Abutment
Description: Participants in this clinical trial will receive dental implants and single screw-retained crowns made from one of four different materials: titanium, PEEK (Polyetheretherketone), zirconia, or lithium disilicate (e.max). The implants will be placed in the posterior region of the mandible or maxillae. The study will evaluate the impact of these materials on peri-implant soft tissue health by measuring inflammatory markers in the peri-implant crevicular fluid and assessing clinical outcomes such as bleeding on probing and pocket depth at 3 and 6 months post-implantation.
Study NCT06554041 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental Crown with Zirconia-Abutment
Description: Participants in this clinical trial will receive dental implants and single screw-retained crowns made from one of four different materials: titanium, PEEK (Polyetheretherketone), zirconia, or lithium disilicate (e.max). The implants will be placed in the posterior region of the mandible or maxillae. The study will evaluate the impact of these materials on peri-implant soft tissue health by measuring inflammatory markers in the peri-implant crevicular fluid and assessing clinical outcomes such as bleeding on probing and pocket depth at 3 and 6 months post-implantation.
Study NCT06554041 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental Crown with Lithium-Disilicate-Abutment (e.max)
Description: Participants in this clinical trial will receive dental implants and single screw-retained crowns made from one of four different materials: titanium, PEEK (Polyetheretherketone), zirconia, or lithium disilicate (e.max). The implants will be placed in the posterior region of the mandible or maxillae. The study will evaluate the impact of these materials on peri-implant soft tissue health by measuring inflammatory markers in the peri-implant crevicular fluid and assessing clinical outcomes such as bleeding on probing and pocket depth at 3 and 6 months post-implantation.
Study NCT04925765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Biofeedback Session
Description: The Flowly intervention treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain/anxiety/depression.
Study NCT05120934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline 50 MG
Description: 50 mg orally for 4 weeks
Study NCT05120934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine 30 MG
Description: 30mg orally for 4 weeks
Study NCT05120934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 MG
Description: 60mg orally for 4 weeks
Study NCT05120934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 30 MG
Description: 30mg tablet with no active study ingredient for 4 weeks
Study NCT05120934 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 30 MG
Description: 30mg tablet with no active study ingredient for 4 weeks
Study NCT05120934 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 60 MG
Description: 60mg tablet with no active study ingredient for 4 weeks
Study NCT06244940 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Whole Genome Sequencing (WGC) from subject samples
Description: Perform whole genome sequencing (WGS) on fetuses with prenatally detected congenital heart disease (CHD) who meet inclusion criteria. Assess diagnostic yield of WGS in CHD and effect of prenatal versus postnatal phenotype on diagnostic yield.
Study NCT04920812 — intervention group
Intervention type: GENETIC
Intervention: diagnosis of mitochondrial myopathy
Description: • Determination of the presence of specific molecular signatures at the RNA level in muscles and fibroblasts from patients
Study NCT05303753 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: fermented dairy protein with prebiotic fiber
Description: During the intervention period, the participant will consume a new product and will reduce the amount of protein in their normal diet reflecting the protein content of the new product.
Study NCT04862819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: new local drug delivery
Description: In the first group, on one side of the dental arch, the drug under evaluation will be used, and on the other side srp
Study NCT04862819 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: scaling root planing
Description: In the second group, on one side of the dental arch srp will be performed
Study NCT04862819 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: scaling root planing
Description: In the second group, on one side of the dental arch srp will be performed
Study NCT05630508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interactive Mhealth Lifestyle behavior intervention
Description: Receiving Standard care, LIVEN educational material and interactive LIVEN application, via having a human component which is a health coach for 3 months
Study NCT05031247 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wellbeing Program
Description: The community navigator program was developed during a three-phase community-based participatory research project that aims to examine emotional/mental health needs and address access to mental health services among immigrants and refugees from Muslim-majority countries.
Study NCT06139055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSBR-1290 (Capsule/Tablet)
Description: Participants will receive GSBR-1290 oral capsules or tablets.
Study NCT06139055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSBR-1290
Description: Participants will receive GSBR-1290 oral tablets.
Study NCT06139055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching-placebo oral tablets.
Study NCT05630508 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Receiving standard care, LIVEN educational material and access to the application
Study NCT06139055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Capsule/Tablet)
Description: Participants will receive matching-placebo oral capsules or tablets.
Study NCT05571072 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opioid calculator
Description: Our research group previously created an Opioid calculator that can be used to predict the number of opioids needed post-operatively based on patient health history and characteristics.
Study NCT05571072 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard opioid prescription
Description: Patients will receive prescription for post-operative opioids based on what the attending surgeon usually provides.
Study NCT06073769 — intervention group
Intervention type: DRUG
Intervention: Oral azacitidine
Description: Maintenance therapy according to the approved label
Study NCT05558969 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregnant women taking magnesium
Description: The patient group who received magnesium as a 4-6 g loading and 2-3 g/h maintenance dose to prevent convulsions in preeclampsia. Pregnant will be operated under general anesthesia. Sugammadex 4mg/kg will be administered when TOF 0 response is seen at the end of surgery. The time from TOF 0 to TOF 0.9 will be recorded. Magnesium and calcium levels in the blood will be studied.
Study NCT05558969 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pregnant women who do not receive magnesium therapy and who will be operated under general anesthesia. Sugammadex 4mg/kg will be administered when TOF 0 response is seen at the end of surgery. The time from TOF 0 to TOF 0.9 will be recorded. Magnesium and calcium levels in the blood will be studied.
Study NCT06218979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone oral solution
Description: See arm/group descriptions
Study NCT06218979 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Risperidone oral solution
Description: See arm/group descriptions
Study NCT04963777 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic
Description: Chicory root derived inulin-type fructan (13.2 kcal/day for ages 8-13 years; 26.4 kcal/day for ages ≥14 years)
Study NCT04963777 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin (isocaloric; 13.2 kcal/day for ages 8-13 years; 26.4 kcal/day for ≥14 years)
Study NCT04802161 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT04802161 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT04802161 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspirate and biopsy
Study NCT04802161 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspirate and biopsy
Study NCT04802161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated Daunorubicin-Cytarabine
Description: Given IV
Study NCT04802161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposome-encapsulated Daunorubicin-Cytarabine
Description: Given IV